In my cart

You have no items in your shopping cart.


Product overview

  • Name
    GSK J4
  • Short description
    JMJD3 / UTX Histone demethylase inhibitor
  • Biological description
    JMJD3 and UTX histone demethylase inhibitor,GSK J1 prodrug. Cell permeable. Reduces macrophage proinflammatory cytokine production. Improves survival in Cardio-facio-cutaneous (CFC) syndrome in mice and inhibits growth of T-cell acute lymphoblastic leukaemia cancer cells.
  • Alternative names
    GSK-J4; GSKJ4
  • Biological action
  • Purity
  • Citations


  • Chemical name
    N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanin e ethyl ester
  • Molecular Weight
  • Chemical structure
    GSK J4  [1373423-53-0]
  • Molecular Formula
  • CAS Number
  • PubChem identifier
  • InChiKey

Storing and Using Your Product

  • Storage instructions
    room temperature
  • Solubility overview
    soluble in DMSO (100mM) or ethanol (100mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for GSK J4

  • A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

    Kruidenier L et al (2012) Nature 488(7411) : 404-8.
    PubMedID: 22842901
  • New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.

    Inoue S et al (2014) Hum Mol Genet 23(24) : 6553-66.
    PubMedID: 25035421
  • Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia.

    Ntziachristos P et al (2014) Nature 514(7523) : 513-7.
    PubMedID: 25132549
Support & Resources

Reviews & Product Guides